



## Cadila Healthcare Limited

Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.  
Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

### Unaudited | Provisional | Financial Results for the Quarter ended September 30, 2009.

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [ except for share data ]							Rupees in Lacs [ except for share data ]				
3 Months Period ended on September 30, 2009 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2008 [Unaudited]	6 Months Period ended on September 30, 2009 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2008 [Unaudited]	Previous Accounting Year ended on March 31, 2009 [Audited]			3 Months Period ended on September 30, 2009 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2008 [Unaudited]	6 Months Period ended on September 30, 2009 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2008 [Unaudited]	Previous Accounting Year ended on March 31, 2009 [Audited]
92,500	75,860	181,459	145,638	291,711	1	Sales & Income from operations :	48,898	48,486	95,899	92,330	173,744
1,242	2,075	2,170	3,280	5,471		A	Gross Sales	747	1,414	1,221	2,345
91,258	73,785	179,289	142,358	286,240	B	Less : Excise Duty	48,151	47,072	94,678	89,985	169,852
3,320	308	5,643	3,141	6,509	C	Net Sales	16,245	6,954	29,292	12,314	24,720
94,578	74,093	184,932	145,499	292,749	D	Other Income from Operations	64,396	54,026	123,970	102,299	194,572
(1,654)	(6,094)	(4,273)	(3,742)	(4,607)	E	Total sales and other income from operations	2,279	(3,510)	2,020	(210)	1,792
22,845	15,195	44,910	31,787	66,946	2	Expenditure :	16,744	14,030	32,561	22,866	49,836
9,010	14,166	17,842	18,990	33,320	A	Increase [-] / Decrease [+] in stock in trade & work in progress	2,309	5,560	4,623	10,060	13,350
11,120	9,260	21,366	18,105	35,208	B	Consumption of materials	6,724	5,933	13,213	11,824	21,803
3,112	2,590	6,074	5,048	11,182	C	Purchase of traded goods	2,204	1,930	4,301	3,848	8,256
32,692	26,316	64,149	48,940	101,304	D	Employees cost	21,050	20,079	40,306	36,773	65,763
17,125	61,433	150,068	119,128	243,353	E	Depreciation & Amortisation	51,310	44,022	97,024	85,161	160,800
17,453	12,660	34,864	26,371	49,396	F	Other Expenditure	13,086	10,004	26,946	17,138	33,772
411	272	833	434	2,036	G	Total Expenditure	1,110	1,307	2,374	2,512	5,953
17,864	12,932	35,697	26,805	51,432	3	Profit from Operations before Other Income, Interest & Exceptional Items [ 1 - 2 ]	14,196	11,311	29,320	19,650	39,725
2,055	1,259	4,349	2,875	9,778	4	Other Income	968	868	2,322	2,212	7,288
253	1,135	394	2,452	2,270	5	Profit before Interest & Exceptional Items [ 3 + 4 ]	158	(147)	322	774	1,514
2,308	2,394	4,743	5,327	12,048	6	Total Financial cost	1,126	721	2,644	2,986	8,802
15,556	10,538	30,954	21,478	39,384	7	Profit after Interest but before Exceptional Items [ 5 - 6 ]	13,070	10,590	26,676	16,664	30,923
(258)	(182)	(350)	(182)	(2,408)	8	Exceptional Items	0	0	0	0	(1,282)
15,298	10,356	30,604	21,296	36,976	9	Net Profit [ + ] / Loss [ - ] from Ordinary Activities before tax [ 7 + 8 ]	13,070	10,590	26,676	16,664	29,641
1,756	1,008	4,180	2,241	6,658	10	Tax expense	630	1,040	1,980	1,550	3,050
13,542	9,348	26,424	19,055	30,318	11	Net Profit [ + ] / Loss [ - ] from Ordinary Activities after tax [ 9 - 10 ]	12,440	9,550	24,696	15,114	26,591
0	0	0	0	0	12	Extraordinary Items [ net of tax expense ]	0	0	0	0	0
13,542	9,348	26,424	19,055	30,318	13	Net Profit [ + ] / Loss [ - ] for the period [ 11 - 12 ]	12,440	9,550	24,696	15,114	26,591
(350)	140	(753)	(600)	(10)	14	Adjustments on consolidation	0	0	0	0	0
13,192	9,488	25,671	18,455	30,308	15	Net Profit [ + ] / Loss [ - ] for the period [ 13 + 14 ]	12,440	9,550	24,696	15,114	26,591
6,824	6,280	6,824	6,280	6,824	16	Paid-up equity share capital [ Face Value Rs. 5 / - ]	6,824	6,280	6,824	6,280	6,824
9.66	6.95*	18.81	13.52*	22.20	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	34,406,982	35,150,458	34,406,982	35,150,458	34,629,818
9.66	6.95*	18.81	13.52*	22.20	18	Earnings Per Share [ EPS ] [ For the period - not Annualised ]:	25.21%	27.98%	25.21%	27.98%	25.37%
34,406,982	35,150,458	34,406,982	35,150,458	34,629,818	19	Public shareholding :	9.11	7.00*	18.09	11.07*	19.48
25.21%	27.98%	25.21%	27.98%	25.37%	A	- Number of shares	9.11	7.00*	18.09	11.07*	19.48
Nil	Nil	Nil	Nil	Nil	B	Basic and diluted EPS before Extraordinary Items [ Rs. ]	9.11	7.00*	18.09	11.07*	19.48
N.A.	N.A.	N.A.	N.A.	N.A.	20	Basic and diluted EPS after Extraordinary Items [ Rs. ]	N.A.	N.A.	N.A.	N.A.	N.A.
N.A.	N.A.	N.A.	N.A.	N.A.	A	Pledged / Encumbered :	N.A.	N.A.	N.A.	N.A.	N.A.
102,092,031	90,463,250	102,092,031	90,463,250	101,869,195	B	Non-encumbered :	102,092,031	90,463,250	102,092,031	90,463,250	101,869,195
100%	100%	100%	100%	100%	-	- Number of shares	100%	100.00%	100%	100.00%	100%
74.79%	72.02%	74.79%	72.02%	74.63%	-	- Percentage of shares [ as a % of the total shareholding of promoters and promoter group ]	74.79%	72.02%	74.79%	72.02%	74.63%
74.79%	72.02%	74.79%	72.02%	74.63%	-	- Percentage of shares [ as a % of the total share capital of the company ]	74.79%	72.02%	74.79%	72.02%	74.63%

#### Notes :

- [ 1 ] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website : www.zyduscadila.com and/or on the websites of BSE [ www.bseindia.com ] and/or NSE [ www.nseindia.com ].
- [ 2 ] The above results for the quarter / half year ended on September 30, 2009 were reviewed by the Audit Committee on October 26, 2009 and then approved by the Board of Directors at their meeting held on October 27, 2009 and the Statutory Auditors of the company have carried out limited review of the financial results of the Company for the quarter / half year ended September 30, 2009.
- [ 3 ]\* Earning per share in item 18 A & B for the three / six months period ended on September 30, 2008 is calculated taking into account the allotment of additional shares issued by the company pursuant to composite scheme of arrangement, to make the figures comparable.
- [ 4 ] The status of investor complaints :  
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 28, pending at the end of the quarter - Nil.
- [ 5 ] The Company has one segment of activity viz. " Pharmaceuticals ".
- [ 6 ] The standalone figures of Cadila Healthcare Limited for the current quarter are not comparable with the figures of corresponding quarter of previous year because of demerger of Consumer Product Division, which got merged with Zydus Wellness Limited, a subsidiary of Cadila Healthcare Limited.

By Order of the Board,  
For Cadila Healthcare Limited,

Pankaj R. Patel  
Chairman & Managing Director

Ahmedabad, October 27, 2009.